Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Luspatercept and mitapivat for the treatment of patients with beta-thalassemia

Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the approval of luspatercept for the treatment of beta-thalassemia, as well as the ongoing Phase III trials of mitapivat- a pyruvate kinase activator- in both transfusion-dependent and independent patients. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.